Veracyte, Inc. (NASDAQ:VCYT) is ranked among the best innovative stocks to buy according to Wall Street analysts. UBS reaffirmed its Buy rating for VCYT with a price target of $48 on January 12. The company’s Q4 testing revenue exceeded expectations due to higher average selling prices and prior-period collections.

VCYT reported preliminary fourth-quarter 2025 revenue of $138-140 million, a 16%-18% increase year-over-year. The company’s 2026 testing revenue projections surpassed street expectations, with a projected adjusted EBITDA margin of 25% by 2026. UBS sees potential gains from new product contributions, indicating growth prospects.

Veracyte, Inc. (NASDAQ:VCYT) is a genomic diagnostics company specializing in tests for thyroid, lung, and other cancers, as well as autoimmune diseases. While VCYT shows investment potential, other AI stocks may offer greater upside with less downside risk. Consider exploring the best short-term AI stock for potential opportunities.

Read more at Yahoo Finance: UBS Reaffirmed Buy Rating on Veracyte (VCYT) After Strong Q4 Testing Revenue